Haemacure Signs Term Sheet for Proposed Collaboration and Bridge Financing

Haemacure Corporation (TSX:HAE), a Montreal-based specialty bio-therapeutics company, announces that it has entered into a term sheet with Angiotech Pharmaceuticals, Inc. of Vancouver (NASDAQ:ANPI, TSX:ANP) for a senior secured bridge loan from Angiotech in the amount of US$2.5 million. Haemacure expects that the bridge loan will enable it to operate for a period of approximately ten to twelve months from the date of the closing of the loan. The bridge loan will be convertible into Haemacure securities in certain circumstances.     "This is great news for Haemacure. We look forward to closing this bridge financing and collaborating with Angiotech" said Joseph Galli, Chairman and CEO of Haemacure.     The term sheet provides that the closing of the bridge loan is expected to take place by May 31, 2009. Completion of the transaction is conditional on standard closing conditions, including negotiation and execution of loan and security documentation and related collaboration agreements between Haemacure and Angiotech. Haemacure can give no assurance that the various closing conditions will be satisfied or that the transaction will close. In connection with the bridge loan, Angiotech has advanced US$200,000 to Haemacure. 

ZymoGenetics Announces Workforce Reduction and Restructuring

ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today a reduction in its workforce of approximately 32 percent, or 161 employees, as part of a corporate restructuring. ZymoGenetics is reorganizing its operations to focus resources on assets with the potential to generate the greatest value for shareholders. The company expects to realize an annual reduction in operating expenses of approximately $30 million beginning in the third quarter as a result of these actions.

"We're taking steps to reduce our costs, align our spending with our highest corporate priorities and conserve our financial resources," said Douglas E. Williams, chief executive officer of ZymoGenetics. "While it is very difficult taking these actions, they are necessary given challenging market conditions and the changing focus of our business plan. Going forward, we believe that ZymoGenetics will be a stronger, more sustainable company with substantially reduced dependence on the capital markets for funding. We appreciate the significant contributions made by all of our employees, including those departing, toward the company's progress to date and in support of our plan to build a valuable and sustainable business."

ZymoGenetics will continue to build the market for its approved product, RECOTHROM(R) Thrombin, topical (Recombinant), while pursuing the research, development and commercialization of novel biologic therapeutics. The company will discontinue ongoing research activities in oncology and focus future research efforts in immunology, its core strength. Collaborative transactions will receive greater emphasis to facilitate the development and commercialization of the company's product candidates, while retaining significant rights to participate in downstream value generation. The recently announced transaction with Bristol-Myers Squibb for PEG-Interferon lambda serves as a model for this strategy. The company is reducing its internal product development infrastructure related to this shift in strategy, and will pursue increased outsourcing in the future. Headcount has been reduced in most areas of the company, with the greatest impact coming in research, manufacturing and other development-related functions, as well as administrative departments. Resource commitments to RECOTHROM commercial activities and PEG-Interferon lambda development have been maintained, consistent with the company's value generation strategy.

Kensey Nash Corporation F3Q09 (Qtr End 3/31/09)

Total revenues for the quarter were $20.6 million, or comparable to the prior year and as I mentioned earlier inline with our guidance for the quarter. When we look at our net sales for the quarter, sales of biomaterial products were $12.9 million. This represents an increase of 3% year-over-year. Within this biomaterial segment, we have cardiovascular products, which are primarily Angio-Seal component sales. These sales increased 6% year-over-year and our spine medicine products increased 11% year-over-year...........

Angio-Seal royalties were $5.3 million or flat year-over-year. Again, this is due to the negative impact of foreign exchange. If you exclude the negative impact, the actual estimate of royalties would have increased by approximately 7% year-over-year. Again unit sales were up year-over-year and I think that's important to keep in mind in looking at the performance of the Angio-Seal and the performance of St. Jude with these products in the marketplace and the ongoing strength and of the product as it continues to dominate in this sector...........

From the Q & A

Spencer Nam – Summer Street Research

Thanks for taking my questions. Excuse me, just couple of quick questions. First of all, on the Angio-Seal, I was wondering if you could give us any color on the competitive dynamics right now with the Angio-Seal evolution out there? And how definitions are comparing Angio-Seal versus some of the passive closure devices? Are you seeing any change in the – how physicians are preferring one part of another recognizing that Angio-Seal does have the super majority of the market at this point?

Joseph Kaufmann

I can only give you my view of this world. I certainly can’t speak for St. Jude. And I really don’t have a lot of information on Evolution. As far as the – how that product is doing specifically in the marketplace. But I can tell you in terms of what we see or hear in the marketplace is that, with a product like Angio-Seal and the reason why it continues to do so well and continue to dominate the market is, because quite frankly it’s a very good product. It has great, great clinical data, great labeling, it’s easy to use. The passive devices and always has been our position at Kensey Nash is they don’t work. They are – they become relatively expensive band-aids as opposed to doing the job that closure devices are intended to do. So, that’s why we think we have been able to or St. Jude has been able to command such great market share in a continuing large market share. So, I’m sure there is always going to be other competition that comes into the market and we will, - we could do well for either a short period of time or may somewhere down the road come up with a better idea, but I haven’t seen it yet.

Source: Seeking Alpha

St Jude Q1 '09 - edited

Total sales of cardiovascular products for the first quarter of 2009 were $240 million, up 15% over the first quarter of 2008 including $12 million of unfavorable foreign currency translations. On a constant currency basis, first quarter cardiovascular product sales increased 21% versus last year. This product category includes sales of products that St. Jude Medical acquired from Radi Medical Systems in December 2008. Within this category of products sales of vascular closure products in the first quarter of 2009 were $98 million, up 9% over the first quarter of 2008. Sales of heart valve products in the first quarter of 2009 were $81 million, a 4% increase over the first quarter of 2008.

For the second quarter of 2009, we expect cardiovascular product sales to be in the range of $235 million to $250 million. We now expect full year 2009 cardiovascular product sales to be in the range of $955 million to $985 million. This 2009 outlook range is slightly less than the full year 2009 guidance range we provided last quarter which primarily reflects the stronger US dollar versus the yen.

ZymoGenetics to Host Conference Call and Webcast on May 5, 2009 Q1 results

ZymoGenetics, Inc. (NASDAQ: ZGEN) announced today that it will report first quarter 2009 financial results on Tuesday, May 5, 2009 after market close. Following the announcement, members of the company’s senior management will discuss the results and provide a corporate update.

Conference Call and Webcast Information

ZymoGenetics 2009 First Quarter Financial Results Conference Call will be held on May 5, 2009 at 4:30 p.m. Eastern Time and may be accessed at www.zymogenetics.com or by dialing 877-407-0778 (International: 201-689-8565). Participants should dial in to the call approximately 10 minutes prior to the scheduled start time to register. A live audio webcast can be accessed by going to:www.zymogenetics.com. The webcast will be archived for 60 days.

For replay, please visit www.zymogenetics.com or use the following information:

• U.S. callers: 1-877-660-6853
• International callers: 1-201-612-7415

Replay passcode account #: 286

Conference ID #: 319537

CSL Behring Marks World Hemophilia Day with $2M Coagulation Factor Donation to World Federation of Hemophilia

In recognition of the World Federation of Hemophilia’s (WFH) progress in improving the diagnosis and treatment of hemophilia in developing countries through its Global Alliance for Progress (GAP) program,CSL Behring has committed to donating to WFH two (2) million units of factor VIII concentrate (FVIII) each year for the next three (3) years. The donation, the total value of which will be approximately $2 million, will be made using coagulation factor concentrate with a minimum shelf-life of one year. CSL Behring has also renewed its pledge to continue supporting the WFH with separate financial contributions totaling nearly $1 million over a period of three years. “As a long-standing contributor to GAP, CSL Behring applauds WFH’s critically important efforts in bringing about improvements and change in the delivery of healthcare services and medicines to hemophilia patients in areas of the world where the need is greatest,” said Peter Turner, President and Chief Executive Officer of CSL Behring. “Serving patients with rare bleeding disorders is a core focus for CSL Behring, as well, and we are extremely pleased to offer our support to GAP, a program that is truly making a large and positive difference.”

Gov't to pay 40%, firms 60% of benefits for hepatitis victims

TOKYO —

The government will shoulder about 40% and two drug companies 60% of relief money they agreed to pay patients infected with hepatitis C through tainted blood products in line with out-of-court settlements in 2008, the health ministry said Friday. The government will put up one-third and the companies—Osaka-based Mitsubishi Tanabe Pharma Corp and Tokyo-based Nihon Pharmaceutical Co—two-thirds of the benefits for the patients given hepatitis C virus-tainted fibrinogen between April 22, 1987 and June 23, 1988, said the Ministry of Health, Labor and Welfare.

Welsh scientist pioneers lifesaving synthetic blood

A REVOLUTIONARY scientific breakthrough, which would create an unlimited supply of synthetic human blood, moved a step closer last night. A group of researchers, led by Welsh scientist Professor Marc Turner, plan to use stem cells to become the first team in the world to create a supply of disease-free blood that cannot be rejected during transfusions. Last night it was announced the group had been awarded a £3m funding boost, allowing the pioneering research to be taken to the next level. The researchers will use stem cells from embryos left over from IVF, then screen them to find those genetically programmed to create the rare O negative blood group. O negative is regarded as the universal donor group which can be transfused into anyone without fear of rejection. The scientists will be able to create an unlimited supply because of the ability of stem cells to reproduce indefinitely in the laboratory. Prof Turner, originally from Cardiff, told the Western Mail that even though his team’s plans were at an early stage, last night they received an “encouraging” £3m funding boost from the Wellcome Trust, the world’s biggest medical research charity. “We have known about this deal for some time but it was made official today,” he said yesterday. “I cannot overstate how early a stage we are at, but this deal, which is worth millions, will help us take our research to the next level.” The academics’ work will culminate in about three years, when they will make the first transfusions of synthetic blood into human volunteers. If successful, their supply could help endless victims of road accidents and military casualties in the field, and be useful in situations where clean blood is not freely available. It will avoid the transmission of life-threatening diseases such as HIV, hepatitis and variant CJD – the human form of mad cow disease – during transfusions. Prof Turner of the University of Edinburgh, who is scientific director of the Scottish National Blood Transfusion Service, added: “From a personal point of view I think it is hugely encouraging and exciting that we have been able to use our knowledge of stem cells and haematology to get to this stage. “Our research is based on something we have been looking to do for about three or four years, looking at an ability to generate red blood cells from so-called adult stem cells, and I really think we have got to the point where we can do this in a research laboratory. “The next step will be transferring this into a clinical environment in an appropriate quality for human trials, which hopefully we will do in about three years. “We are looking forward to being able to get started on the real work when the grant kicks in this July.” Scientists, mainly in Sweden, France and Australia, have been working on similar plans to create synthetic blood, also using stem cells. And last year, the US company Advanced Cell Technology announced it had been able to create blood cells using embryonic stem cells. Their plans were held up because of former President George Bush’s opposition to embryonic cell work. Barack Obama has since reversed the policy. The multi-collaborative British project could eventually help plug the gap between the numbers donating blood regularly and the supply needed by hospitals. The National Blood Service for Wales said: “This is a very encouraging piece of research which has the possibility to show great promise for the future.” The Welsh Blood Service provides supplies of blood and its products to 16 hospitals in South, Mid and West Wales. It needs to collect more than 100,000 whole blood donations and 10,000 platelets every year, but only 6% of the nation currently gives blood

Vascular Solutions Announces First Quarter Results; Net Revenue Increases 12% to $15.8 Million; Net Income Increases 300% to $0.06 Per Share

MINNEAPOLIS, April 16, 2009 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc. (Nasdaq:VASC) today reported financial results for the first quarter ended March 31, 2009........  While our net revenue increased by 12% over the first quarter of 2008, it was approximately $700,000 below our expectations. The primary reason for the revenue shortfall was the decision by our partner King Pharmaceuticals to suspend the clinical development of our Thrombi-Paste(tm) product, solely due to economic reasons...............

Net revenue from hemostat products (primarily consisting of the D-Stat Dry, D-Stat Flowable, Thrombi-Gel(r), Thrombi-Pad(r) and D-Stat Radial products) was $5.8 million during the first quarter, essentially even compared to the first quarter of 2008. "The hemostatic patch market continues to be very competitive, but with the imminent exit of a major competitor and the launch of our new D-Stat Dry Wrap version in the first quarter, we believe that we will continue to hold and increase our market-leading position in this market," commented Mr. Root. Vascular Solutions will host a live webcast starting at 3:30 p.m., Central Time today to discuss the information contained in this press release. The live web cast may be accessed on the investor relations portion of the company's web site at www.vascularsolutions.com. An audio replay of the call will be available until Thursday, April 23, 2009 by dialing 1-888-203-1112 and entering conference ID# 8256754. A recording of the call will also be archived on the Company's web site, www.vascularsolutions.com until Thursday, April 23, 2009. During the conference call the Company may answer one or more questions concerning business and financial developments and trends, the Company's view on earnings forecasts and new product development and financial matters affecting the Company, some of the responses to which may contain information that has not been previously disclosed.

New Tool Calculates Risk Of Bleeding In Heart Attack Patients

Led by Sumeet Subherwal, M.D., formerly a Barnes-Jewish Hospital medical resident at Washington University Medical Center and now a cardiology fellow at Duke University, and in collaboration with several investigators including Karen Alexander, M.D., a cardiologist at the Duke Clinical Research Institute, the researchers analyzed the medical histories of more than 89,000 patients hospitalized in the United States for non-ST-elevation heart attack. This type of heart attack is the most common and usually results from a partial rather than complete blockage of the heart's arteries.
The patient histories were part of the CRUSADE Quality Improvement Initiative, a national multicenter program that aims to improve outcomes for heart attack patients. The risk assessment tool is called the CRUSADE bleeding score.
"A lot of treatment decisions have to be made very promptly after the patient arrives," says Bach, also associate professor of medicine in the Cardiovascular Division at Washington University School of Medicine. "So we designed a bleeding-risk stratification tool that would require only those variables that can be obtained up front. It's a practical tool that can be used in any hospital setting."
The CRUSADE analysis identified eight factors that could predict the odds that a heart attack patient might suffer a bleeding event. The factors are gender, heart rate, blood pressure, hematocrit (the concentration of red cells in the blood), creatinine clearance (a measure of kidney function), diabetes, peripheral vascular disease or stroke, and congestive heart failure.
The bleeding score calculation assigns points to each factor so that the total score coincides with risk of bleeding evidenced in the CRUSADE cases. The range of possible scores is divided into five categories from very low to very high risk of bleeding.
The bleeding risk score is intended to help guide critical early treatment decisions for clinicians caring for heart attack patients, but the impact of its use on outcomes will need to be tested in clinical trials, says Bach. Potentially, the score will be used in conjunction with other practice guidelines to optimize heart attack treatment and minimize risk.

Full article HERE